Skip to main content

Table 1 Demographics, clinical baseline characteristics of the study populations

From: Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study)

ParameterSub-parameterImmediate treatmentDeferred treatmentp-value (if applicable)
Age (mean ± SD) (years) 42.9 (± 8.6)42 (± 10.4)0.714
Gender-no./total-no. (%)Male29/31 (93.5)27/30 (90.0)0.671
Female2/31 (6.5)3/30 (10.0)
Race-no./total no. (%)White28/31 (90.3)26/30 (86.7)0.833
Black-African3/31 (9.7)4/30 (13.3)
Viral load before randomizationMean (cop/mL)447,579570,020 
CD4 cells before randomization (baseline)Mean (absolute)2742 
PCP (n = number of patients) 2426 
TE (n = number of patients) 74